Patents by Inventor Lidia Mosyak

Lidia Mosyak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20160311912
    Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.
    Type: Application
    Filed: December 21, 2015
    Publication date: October 27, 2016
    Inventors: Alison Jane Forgie, Javier Fernando Chaparro Riggers, Edward Roland Lavallie, Chia-Yang Lin, Lidia Mosyak, Andrea Rossi, Thomas John Van Blarcom
  • Anti-glucagon receptor antibodies and pharmaceutical compositions thereof
    Patent number: 9248189
    Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: February 2, 2016
    Assignee: PFIZER INC.
    Inventors: Alison Jane Forgie, Javier Fernando Chaparro Riggers, Edward Roland Lavallie, Chia-Yang Lin, Lidia Mosyak, Andrea Rossi, Thomas John Van Blarcom
  • BISPECIFIC HETERODIMERIC DIABODIES AND USES THEREOF
    Publication number: 20160002357
    Abstract: Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the P-cadherin tumor cell associated antigen and the CD3 T cell antigen.
    Type: Application
    Filed: June 26, 2015
    Publication date: January 7, 2016
    Applicant: PFIZER INC.
    Inventors: Chad Michael MAY, Adam Reid ROOT, William A. BRADY, Lioudmila Gennadievna TCHISTIAKOVA, Lidia MOSYAK, Laird BLOOM, Paul A. MOORE, Leslie S. JOHNSON
  • DUAL PDGF/VEGF ANTAGONISTS
    Publication number: 20150376271
    Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.
    Type: Application
    Filed: June 29, 2015
    Publication date: December 31, 2015
    Applicant: OLIGASIS, LLC
    Inventors: D. Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
  • ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF
    Publication number: 20140335091
    Abstract: The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome.
    Type: Application
    Filed: May 2, 2014
    Publication date: November 13, 2014
    Applicant: RINAT NEUROSCIENCE CORP.
    Inventors: Alison Jane FORGIE, Javier Fernando CHAPARRO RIGGERS, Edward Roland LAVALLIE, Chia-Yang LIN, Lidia MOSYAK, Andrea ROSSI, Thomas John VAN BLARCOM
  • Method for identifying or designing a candidate agent that interacts with LINGO-1 polypeptide using a LINGO-1 three-dimensional structure
    Patent number: 7693698
    Abstract: This disclosure relates to LINGO-1 polypeptides, LINGO-1 polypeptide/ligand complexes, crystals of LINGO-1 polypeptides, crystals of LINGO-1 polypeptide/ligand complexes, and related methods and software systems.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: April 6, 2010
    Assignee: Wyeth LLC
    Inventors: Lidia Mosyak, Brian Dwyer, Mark Johnson, Xiaotian Zhong, Eleonora Presman, James M. Wilhelm, Mark Stahl, William Stuart Somers
  • Aggrecanase structure
    Patent number: 7615363
    Abstract: This invention relates to aggrecanase polypeptides and aggrecanase polypeptide/ligand complexes, crystals of aggrecanase and aggrecanase polypeptide/ligand complexes, and related methods and software systems.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: November 10, 2009
    Assignee: Wyeth
    Inventors: Lidia Mosyak, Thomas Saltmarsh Rush, III, Xiaotian Zhong, Thomas E. McDonagh, Katy E. Georgiadis, Phaik-Eng Sum, Edward R. LaVallie, Lisa A. Collins-Racie, Christopher John Corcoran, Ravindra Kumar, Tracy Hebert, Stephane Hubert Olland, Stewart Andrews Mackie
  • Structure of protein kinase C theta
    Patent number: 7584087
    Abstract: A three-dimensional structure of human protein kinase C theta (PKC?) can be used in methods of designing an agent that interacts with PKC?. The agent can be an inhibitor of PKC? activity.
    Type: Grant
    Filed: April 6, 2005
    Date of Patent: September 1, 2009
    Assignee: Wyeth
    Inventors: Zhang Bao Xu, Stephane Olland, Scott Wolfrom, Karl Malakian, Laura Lin, Mark Stahl, Julie Lee, Lori Fitz, Rita Greco, Divya Chaudhary, William Stuart Somers, Lidia Mosyak
  • Methods for the design of estrogen receptor ligands
    Patent number: 7555415
    Abstract: Estrogen receptor ligands, estrogen receptor polypeptide/ligand complexes, crystals of estrogen receptor polypeptide/ligand complexes, and related methods and software systems are disclosed.
    Type: Grant
    Filed: January 18, 2006
    Date of Patent: June 30, 2009
    Assignee: Wyeth
    Inventors: Lidia Mosyak, Zhang Bao Xu, Mark Stahl, Wah-Tung Hum, William Stuart Somers, Eric Steven Manas
  • LINGO-1 structure
    Publication number: 20070274918
    Abstract: This disclosure relates to LINGO-1 polypeptides, LINGO-1 polypeptide/ligand complexes, crystals of LINGO-1 polypeptides, crystals of LINGO-1 polypeptide/ligand complexes, and related methods and software systems.
    Type: Application
    Filed: February 1, 2007
    Publication date: November 29, 2007
    Inventors: Lidia Mosyak, Brian Dwyer, Mark Johnson, Xiaotian Zhong, Eleonora Presman, James Wilhelm, Mark Stahl, William Somers
  • Crystal structures of MK2 and uses thereof
    Publication number: 20070100560
    Abstract: This invention is directed to the crystal structures of MK2, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of MK2 proteins. Such agents may be useful as therapeutic agents.
    Type: Application
    Filed: December 6, 2006
    Publication date: May 3, 2007
    Inventors: Kevin Parris, Kathryn Underwood, Mark Stahl, Lidia Mosyak, Kristine Svenson, Tania Shane, Meggin Taylor
  • Anti-IL-13 antibodies and complexes
    Publication number: 20070048785
    Abstract: Anti-IL-13 antibodies, crystals of anti-IL-13 antibodies, IL-13 polypeptide/anti-IL-13 antibody complexes, crystals of IL-13 polypeptide/anti-IL-13 antibody complexes, IL-13R?1 polypeptide/IL-13 polypeptide/anti-IL-13 antibody complexes, crystals of IL-13R?1 polypeptide/IL-13 polypeptide/anti-IL-13 antibody complexes, and related methods and software systems are disclosed.
    Type: Application
    Filed: June 9, 2005
    Publication date: March 1, 2007
    Inventors: Laura Lin, Kevin Parris, Amy Sze Tam, Xiang-Yang Tan, Tania Shane, John Dumas, James Wilhelm, Mark Stahl, Lidia Mosyak, Zhixiang Hu
  • Methods for identifying agents that interact with MAP kinase activated protein kinase 2
    Patent number: 7167802
    Abstract: This invention is directed to the crystal structures of MK2, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of MK2 proteins. Such agents may be useful as therapeutic agents.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: January 23, 2007
    Assignee: Wyeth
    Inventors: Kevin D. Parris, Kathryn W. Underwood, Mark L. Stahl, Lidia Mosyak, Kristine Svenson, Tania Shane, Meggin L. Taylor
  • Estrogen receptor structure
    Publication number: 20060160836
    Abstract: Estrogen receptor ligands, estrogen receptor polypeptide/ligand complexes, crystals of estrogen receptor polypeptide/ligand complexes, and related methods and software systems are disclosed.
    Type: Application
    Filed: January 18, 2006
    Publication date: July 20, 2006
    Inventors: Lidia Mosyak, Zhang Xu, Mark Stahl, Wah-Tung Hum, William Somers, Eric Manas
  • Structure of protein kinase C theta
    Publication number: 20060003431
    Abstract: A three-dimensional structure of protein kinase C theta (PKC?) can be used in methods of designing an agent that interacts with PKC?. The agent can be an inhibitor of PKC? activity.
    Type: Application
    Filed: April 6, 2005
    Publication date: January 5, 2006
    Inventors: Zhang Xu, Stephane Olland, Scott Wolfrom, Karl Malakian, Laura Lin, Mark Stahl, Julie Lee, Lori Fitz, Rita Greco, Divya Chaudhary, William Somers, Lidia Mosyak
  • Crystal structures of Kv channel proteins and uses thereof
    Publication number: 20040091908
    Abstract: This invention is directed to the crystal structures of Kv channel proteins, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of Kv channel proteins. Such agents may be useful as therapeutic agents.
    Type: Application
    Filed: July 1, 2003
    Publication date: May 13, 2004
    Inventors: Weixin Xu, Zhangbao Xu, Laura Long Lin, Stephane Hubert Olland, Lidia Mosyak, William Stuart Somers
  • Crystal structures of MK2 and uses thereof
    Publication number: 20040091872
    Abstract: This invention is directed to the crystal structures of MK2, and to the use of these structures in rational drug design methods to identify agents that may interact with active sites of MK2 proteins. Such agents may be useful as therapeutic agents.
    Type: Application
    Filed: November 13, 2002
    Publication date: May 13, 2004
    Inventors: Kevin D. Parris, Kathryn W. Underwood, Mark L. Stahl, Lidia Mosyak, Kristine Svenson, Tania Shane, Meggin L. Taylor